文献速递甲状腺与颈部外科围术期管理与 ERAS

甲状旁腺切除术对比西那卡塞对非透析终末期肾病患者心血管结局的影响

Beyond the Gland: How Parathyroidectomy Enhances Cardiovascular Health in Dialysis-Independent End-Stage Renal Disease Patients.
PubMed 文献 · J Am Coll Surg · 2026-04-09

本研究为回顾性队列研究,利用TriNetX全球研究网络,纳入非透析依赖的终末期肾病合并三发性甲状旁腺功能亢进成人患者,比较甲状旁腺切除术与西那卡塞治疗。经倾向性评分匹配后每组880例,随访至5年。甲状旁腺切除术与较低的主要不良心血管事件风险相关(HR 0.64,95%CI 0.52-0.78,p<0.001),心肌梗死和心衰住院风险亦降低。结论支持考虑手术以减轻长期心血管风险。

要点

  • 甲状旁腺切除术较西那卡塞降低主要不良心血管事件风险(HR 0.64)。
  • 手术组心肌梗死和心衰住院风险均显著低于西那卡塞组。
  • 非透析终末期肾病合并三发性甲旁亢可考虑手术以改善心血管预后。

核心结论

  • 在非透析依赖的三发性甲状旁腺功能亢进患者中,甲状旁腺切除术相比西那卡塞与长期心血管事件持续减少相关。

研究设计与样本

  • 回顾性队列研究,使用TriNetX全球研究网络,纳入非透析依赖终末期肾病合并三发性甲状旁腺功能亢进成人患者,按治疗分组并行1:1倾向性评分匹配,每组880例,随访至5年。

主要发现

  • 匹配后每组880例,平均年龄53±14岁,女性比例分别为49.0%和51.3%。
  • 甲状旁腺切除术组主要不良心血管事件风险低于西那卡塞组(HR 0.64,95%CI 0.52-0.78,p<0.001)。
  • 心肌梗死发生率12.5% vs 15.4%(HR 0.64,95%CI 0.52-0.78),心衰住院20.0% vs 26.3%(HR 0.62,95%CI 0.55-0.71)。
  • 冠状动脉旁路移植术0% vs 2.2%(p=0.001),经皮冠状动脉介入1.8% vs 2.8%(HR 0.79,95%CI 0.72-0.90)。
  • 次要结局显示房颤(HR 0.33,95%CI 0.21-0.55)、室性心律失常(HR 0.73,95%CI 0.70-0.85)、高血压性心脏病(HR 0.49,95%CI 0.41-0.59)、心衰(HR 0.64,95%CI 0.59-0.76)和外周血管病(HR 0.73,95%CI 0.67-0.92)风险均降低。

临床怎么用

  • 对于非透析依赖的终末期肾病合并三发性甲状旁腺功能亢进患者,甲状旁腺切除术可作为降低长期心血管风险的考虑选项。

局限性

  • 本研究为回顾性队列研究,可能存在未测量的混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The comparative effect of parathyroidectomy vs cinacalcet on long-term cardiovascular outcomes in dialysis-independent tertiary hyperparathyroidism remains unclear. STUDY DESIGN: A retrospective cohort study was performed using the TriNetX global research network. Adults with tertiary hyperparathyroidism and dialysis-independent end-stage renal disease were identified and stratified by treatment (parathyroidectomy vs cinacalcet). Propensity score matching (1:1) balanced demographics, comorbidities, cardiovascular history, and medication use. Time-to-event analyses were conducted using Cox proportional hazards regression for up to 5 years of follow-up. RESULTS: After matching, 880 patients were included in each cohort (mean age 53 ± 14 years; female patients 49.0% vs 51.3%). Parathyroidectomy was associated with a lower risk of major adverse cardiovascular events compared with cinacalcet (hazard ratio [HR] 0.64, 95% CI 0.52 to 0.78; p < 0.001). MI (12.5% vs 15.4%; HR 0.64, 95% CI 0.52 to 0.78) and heart failure hospitalization (20.0% vs 26.3%; HR 0.62, 95% CI 0.55 to 0.71) were reduced after parathyroidectomy. Coronary revascularization was less frequent (coronary artery bypass graft 0% vs 2.2%, p = 0.001; percutaneous coronary intervention 1.8% vs 2.8%, HR 0.79, 95% CI 0.72 to 0.90). Secondary outcomes demonstrated lower hazards of atrial fibrillation (HR 0.33, 95% CI 0.21 to 0.55), ventricular arrhythmia (HR 0.73, 95% CI 0.70 to 0.85), hypertensive heart disease (HR 0.49, 95% CI 0.41 to 0.59), heart failure (HR 0.64, 95% CI 0.59 to 0.76), and peripheral vascular disease (HR 0.73, 95% CI 0.67 to 0.92). Findings were consistent in sensitivity and competing-risk analyses. CONCLUSIONS: Parathyroidectomy was associated with a durable reduction in cardiovascular events compared with cinacalcet in dialysis-independent tertiary hyperparathyroidism. These findings support consideration of surgical management to mitigate long-term cardiovascular risk.

来源:J Am Coll Surg,查看原文。版权归原作者所有。

引用

  1. Swaminathan N, Nathani S, Caretti R, et al. Beyond the Gland: How Parathyroidectomy Enhances Cardiovascular Health in Dialysis-Independent End-Stage Renal Disease Patients. J Am Coll Surg. 2026. PMID: 41954269. doi:10.1097/XCS.0000000000001965

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。